These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 37057810)
1. Dihydroartemisinin enhances gefitinib cytotoxicity against lung adenocarcinoma cells by inducing ROS-dependent apoptosis and ferroptosis. Lai XY; Shi YM; Zhou MM Kaohsiung J Med Sci; 2023 Jul; 39(7):699-709. PubMed ID: 37057810 [TBL] [Abstract][Full Text] [Related]
2. Co-treatment of betulin and gefitinib is effective against EGFR wild-type/KRAS-mutant non-small cell lung cancer by inducing ferroptosis. Yan WY; Cai J; Wang JN; Gong YS; Ding XB Neoplasma; 2022 May; 69(3):648-656. PubMed ID: 35330996 [TBL] [Abstract][Full Text] [Related]
3. YES1 as a potential target to overcome drug resistance in EGFR-deregulated non-small cell lung cancer. Kook E; Lee J; Kim DH Arch Toxicol; 2024 May; 98(5):1437-1455. PubMed ID: 38443724 [TBL] [Abstract][Full Text] [Related]
4. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy. Lee JY; Lee YM; Chang GC; Yu SL; Hsieh WY; Chen JJ; Chen HW; Yang PC PLoS One; 2011; 6(8):e23756. PubMed ID: 21858220 [TBL] [Abstract][Full Text] [Related]
5. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer. Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272 [TBL] [Abstract][Full Text] [Related]
6. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells. Li A; Cao W; Liu X; Zhang Y; Ma Y; Xu R; Zhang R; Liu X; Zhou S; Wang R; Liu J; Tang X J Cancer Res Clin Oncol; 2020 Jul; 146(7):1737-1749. PubMed ID: 32342201 [TBL] [Abstract][Full Text] [Related]
7. Pemetrexed induces ROS generation and cellular senescence by attenuating TS-mediated thymidylate metabolism to reverse gefitinib resistance in NSCLC. Chen Y; Zhang C; Jin S; Li J; Dai J; Zhang Z; Guo R J Cell Mol Med; 2023 Jul; 27(14):2032-2044. PubMed ID: 37278440 [TBL] [Abstract][Full Text] [Related]
8. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374 [TBL] [Abstract][Full Text] [Related]
9. Carbonic Anhydrase IX Controls Vulnerability to Ferroptosis in Gefitinib-Resistant Lung Cancer. Zhang C; Lu X; Liu X; Xu J; Li J; Qu T; Dai J; Guo R Oxid Med Cell Longev; 2023; 2023():1367938. PubMed ID: 36760347 [TBL] [Abstract][Full Text] [Related]
10. FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer. Sun C; Gao W; Liu J; Cheng H; Hao J Respir Res; 2020 Aug; 21(1):210. PubMed ID: 32778129 [TBL] [Abstract][Full Text] [Related]
11. [Effect of SLC7A11 gene downregulation on the gefitinib resistance of lung adenocarcinoma PC9/GR cells and its mechanism]. Jia YL; Zhao Y; Zhen SM; Cheng ZS; Zheng BY; Liu YP; Liu LH Zhonghua Zhong Liu Za Zhi; 2023 Sep; 45(9):779-786. PubMed ID: 37805442 [No Abstract] [Full Text] [Related]
12. GLRX inhibition enhances the effects of geftinib in EGFR-TKI-resistant NSCLC cells through FoxM1 signaling pathway. Wang L; Liu J; Liu J; Chen X; Chang M; Li J; Zhou J; Bai C; Song Y J Cancer Res Clin Oncol; 2019 Apr; 145(4):861-872. PubMed ID: 30661098 [TBL] [Abstract][Full Text] [Related]
13. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer. Liu P; Xiang Y; Liu X; Zhang T; Yang R; Chen S; Xu L; Yu Q; Zhao H; Zhang L; Liu Y; Si Y Molecules; 2019 Feb; 24(3):. PubMed ID: 30759826 [TBL] [Abstract][Full Text] [Related]
14. Delivery of gefitinib in synergism with thymoquinone Upadhyay P; Ghosh A; Basu A; Pranati PA; Gupta P; Das S; Sarker S; Bhattacharjee M; Bhattacharya S; Ghosh S; Chattopadhyay S; Adhikary A Biomater Sci; 2021 Dec; 9(24):8285-8312. PubMed ID: 34766965 [TBL] [Abstract][Full Text] [Related]
15. Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib. Cheng H; An SJ; Dong S; Zhang YF; Zhang XC; Chen ZH; Jian-Su ; Wu YL J Hematol Oncol; 2011 Jan; 4():5. PubMed ID: 21255411 [TBL] [Abstract][Full Text] [Related]
16. [Cigarette Smoke Induces Gefitinib Resistance in NSCLC Cells via ROS/Sirt3/SOD2 Pathway]. Zi Y; Liao K; Chen H Zhongguo Fei Ai Za Zhi; 2023 Apr; 26(4):245-256. PubMed ID: 37183639 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of DDR1 promotes ferroptosis and overcomes gefitinib resistance in non-small cell lung cancer. Zhang Y; Qian J; Fu Y; Wang Z; Hu W; Zhang J; Wang Y; Guo Y; Chen W; Zhang Y; Wang X; Xie Z; Ye H; Ye F; Zuo Z Biochim Biophys Acta Mol Basis Dis; 2024 Oct; 1870(7):167447. PubMed ID: 39089636 [TBL] [Abstract][Full Text] [Related]
18. [STE029 Overcomes EGFR-TKI Resistance in Human Lung Adenocarcinoma]. Huang L; Hou M; Liu J; Li Y; Shen W; Zhou Q Zhongguo Fei Ai Za Zhi; 2022 Nov; 25(11):771-781. PubMed ID: 36419390 [TBL] [Abstract][Full Text] [Related]
19. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3. Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264 [TBL] [Abstract][Full Text] [Related]
20. Xie-Bai-San increases NSCLC cells sensitivity to gefitinib by inhibiting Beclin-1 mediated autophagosome formation. Ma C; Zhang X; Mo X; Yu Y; Xiao Z; Wu J; Ding L; Lei C; Zhu Y; Zhang H Phytomedicine; 2024 Mar; 125():155351. PubMed ID: 38232540 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]